LEGEND BIOTECH SP.ADS/2
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more
LEGEND BIOTECH SP.ADS/2 (9LB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LEGEND BIOTECH SP.ADS/2 (9LB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LEGEND BIOTECH SP.ADS/2 - Net Assets Trend (None–None)
This chart illustrates how LEGEND BIOTECH SP.ADS/2's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LEGEND BIOTECH SP.ADS/2 (None–None)
The table below shows the annual net assets of LEGEND BIOTECH SP.ADS/2 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LEGEND BIOTECH SP.ADS/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LEGEND BIOTECH SP.ADS/2 Competitors by Market Cap
The table below lists competitors of LEGEND BIOTECH SP.ADS/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
$2.81 Billion |
|
Sportradar Group AG
NASDAQ:SRAD
|
$2.81 Billion |
|
Bollore SA
PA:BOL
|
$2.81 Billion |
|
Billionbrains Garage Ventures Ltd
NSE:GROWW
|
$2.81 Billion |
|
NHPC Limited
NSE:NHPC
|
$2.81 Billion |
|
Xiamen Kehua Hengsheng
SHE:002335
|
$2.80 Billion |
|
Hera S.p.A
PINK:HRASF
|
$2.80 Billion |
|
Olin Corporation
NYSE:OLN
|
$2.80 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LEGEND BIOTECH SP.ADS/2's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LEGEND BIOTECH SP.ADS/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LEGEND BIOTECH SP.ADS/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LEGEND BIOTECH SP.ADS/2's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LEGEND BIOTECH SP.ADS/2 (9LB) | €- | N/A | N/A | $2.81 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |